RCD advises on the closing of a €3m financing round for Corify Care
Corify Care, the medical technology company that is transforming the diagnosis and treatment of cardiac arrhythmias, has announced the closing of a €3 million financing round advised by the firm RCD and led by Clave-Mondragon, along with obtaining public grants for a further €3 million.
The new €6 million funding will enable Corify to deploy in Europe and prepare for entry into the U.S. market of ACORYS, its revolutionary technology that performs real-time global mapping of cardiac electrical activity and is transforming the diagnosis and treatment of cardiac arrhythmias.
The secured financing will enable Corify Care to consolidate its expansion in Europe and leap into international markets, with activities planned in Germany and the United States in 2025. In addition, the company has signed strategic agreements with different Mondragon cooperatives, ensuring scalability in device production to respond to growing global demand.
“This year we will almost triple the number of cases performed in 2023 and have surpassed 1,500 patients treated. In 2025, we will start activities in Germany and the United States, consolidating our exponential growth,” commented Andreu Climent, CEO of Corify Care.
The RCD team has been led by Antoni Rosselló, partner in the innovation and entrepreneurship area.
